Peri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorJohn Sapp

About this trial

Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical "short circuit" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. An important treatment is to use catheter ablation to "block" the channel that forms the circuit. Effective ablation requires imaging guidance to visualize the VT circuit relative to scar structures in 3D. Unfortunately, with conventional catheter mapping, up to 90% of the VT circuits are too short-lived to be mapped. For the 10% "mappable" VTs, their data are only available during ablation and limited to one ventricular surface. This inadequacy of functional VT data largely limits the knowledge about scar-related VT and ablation strategies, and reduces the ability of clinicians to identify ablation targets and assess ablation outcome.

The central hypothesis of this proposal is that functional VT data, integrated with CT or MRI scar data in 3D, can improve VT ablation efficacy with pre-procedural identification of ablation targets and post-procedural mechanistic elucidation of ablation failure. This research builds on the rapidly increasing clinical interest in electrocardiographic imaging (ECGi), an emerging technique that obtains cardiac electrical activity through inverse reconstructions from ECGs. The specific objective is to push the boundary of ECGi to provide - as a conjunction to intra-procedural catheter mapping - pre-ablation and post-ablation imaging of functional VT circuits integrated with 3D scar structure.

Eligibility criteria

Qualifiers

One or more episodes of sustained monomorphic VT

Referred for catheter ablation

Previously implanted ICD

Signed the patient informed consent form

Disqualifiers

Have estimated Glomerular Filtration Ratio (eGFR) less than 30

Have a life expectancy less than 6 months or are listed for heart transplantation at time of inclusion

Are pregnant

Are on IV inotropic agents

Trial design

Treatments tested in this trial

  • EP Imaging and Testing

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators

John Sapp

Lead sponsor

Nova Scotia Health Authority

Sponsor institution

Nova Scotia Health Authority

Collaborator

Rochester Institute of Technology

Collaborator